Annual Report 2006 - Boehringer Ingelheim

More documents

Recommendations

Info

3 Notes to the consolidated balance sheet 3.1 Intangible assets (in millions of EUR) Procurement/manufacturing costs Concessions/ Similar rights Goodwill Advance payments Balance as of 1. 1. 2005 526 816 3 1,345 Currency conversion difference 11 3 0 14 Additions due to first consolidation 0 0 0 0 Additions 50 0 7 57 Disposals -18 -13 0 -31 Reclassifications 4 0 -4 0 Balance as of 31. 12. 2005 573 806 6 1,385 Currency conversion difference -30 0 0 -30 Additions due to first consolidation 0 0 0 0 Additions 443 0 8 451 Disposals -18 0 0 -18 Reclassifications 7 0 -3 4 Balance as of 31. 12. 2006 975 806 11 1,792 Accumulated depreciations Balance as of 1. 1. 2005 357 721 0 1,078 Currency conversion difference 9 2 0 11 Additions due to first consolidation 0 0 0 0 Additions 44 48 0 92 Write-ups 0 0 0 0 Disposals -16 -13 0 -29 Reclassifications 0 0 0 0 Balance as of 31. 12. 2005 394 758 0 1,152 Currency conversion difference -10 0 0 -10 Additions due to first consolidation 0 0 0 0 Additions 63 48 0 111 Write-ups 0 0 0 0 Disposals -15 0 0 -15 Reclassifications 0 0 0 0 Balance as of 31. 12. 2006 432 806 0 1,238 Book value as of 31. 12. 2005 179 48 6 233 Book value as of 31. 12. 2006 543 0 11 554 Total Notes to the consolidated financial statements 2006 127
128 3.2 Tangible assets (in millions of EUR) Procurement/manufacturing costs Land and buildings Technical facilities and machines Other facilities/ operating equipment Advance payments/ construction in progress Balance as of 1. 1. 2005 2,022 1,982 1,312 270 5,586 Currency conversion difference 96 82 61 15 254 Additions due to first consolidation 3 2 2 0 7 Additions 37 77 140 278 532 Disposals -31 -42 -89 -8 -170 Reclassifications 56 98 49 -203 0 Balance as of 31. 12. 2005 2,183 2,199 1,475 352 6,209 Currency conversion difference -115 -81 -56 -17 -269 Additions due to first consolidation 0 0 0 0 0 Additions 54 70 164 308 596 Disposals -78 -57 -82 -2 -219 Reclassifications 66 107 89 -266 -4 Balance as of 31. 12. 2006 2,110 2,238 1,590 375 6,313 Accumulated depreciations Balance as of 1. 1. 2005 933 1,030 911 0 2,874 Currency conversion difference 42 43 40 0 125 Additions due to first consolidation 2 1 2 0 5 Additions 125 163 151 0 439 Write-ups 0 -2 0 0 -2 Disposals -13 -37 -82 0 -132 Reclassifications 0 0 0 0 0 Balance as of 31. 12. 2005 1,089 1,198 1,022 0 3,309 Currency conversion difference -58 -45 -38 0 -141 Additions due to first consolidation 0 0 0 0 0 Additions 83 172 164 0 419 Write-ups -1 -1 -1 0 -3 Disposals -36 -48 -73 0 -157 Reclassifications -1 1 0 0 0 Balance as of 31. 12. 2006 1,076 1,277 1,074 0 3,427 Book value as of 31. 12. 2005 1,094 1,001 453 352 2,900 Book value as of 31. 12. 2006 1,034 961 516 375 2,886 Boehringer Ingelheim a n n u a l r e p o r t 2 0 0 6 Total
Page 1 and 2:
Value through Innovation Annual Rep
Page 3 and 4:
Contents 1 Value Through Innovation
Page 5 and 6:
The Shareholders’ Perspective Dea
Page 7 and 8:
Key Aspects of 2006 2006 was again
Page 9 and 10:
This growth was clearly restrained
Page 11 and 12:
Shareholders’ Committee Dr Heribe
Page 13 and 14:
“There is help” “The woman wh
Page 15 and 16:
1 continued from page 10 A Kenyan m
Page 17 and 18:
1 Our people In pursuing our vision
Page 19 and 20:
Company childcare enters new territ
Page 21 and 22:
1 Caring for our neighbours We are
Page 23 and 24:
0 Children from St Margaret Clither
Page 25 and 26:
Our environment & employee safety A
Page 27 and 28:
thanks to the use of the wood-fired
Page 29 and 30:
Our goals We shall continue to inve
Page 31 and 32:
Targeting tomorrow’s therapies Th
Page 33 and 34:
0 continued from page 28 “Boehrin
Page 35 and 36:
Our R & D strategy Research and dev
Page 37 and 38:
Ridgefield, USA Cardiovascular, imm
Page 39 and 40:
Vienna, Austria Oncology Boehringer
Page 41 and 42:
Our expertise in landmark studies L
Page 43 and 44:
From mind to man - the R & D proces
Page 45 and 46:
New biological entities (NBE) One o
Page 47 and 48:
The development of our businesses W
Page 49:
Rin Fujima, Kyoto, Japan, suffers f
Page 52 and 53:
Human Pharmaceuticals Branded presc
Page 54 and 55:
cal exercise capacity and the reduc
Page 56 and 57:
“Like a great round of golf“
Page 58 and 59:
gives patients a better chance of g
Page 60 and 61:
aptivus® was launched in the USA i
Page 62 and 63:
enzymes, such as the HCV serine pro
Page 64 and 65:
Børge Madsen, Copenhagen, Denmark.
Page 66 and 67:
Cardiovascular diseases Despite sig
Page 68 and 69:
actilyse® is the first and only th
Page 70 and 71:
fibrillation in some 40 countries i
Page 72 and 73:
Treatment modalities used to reliev
Page 74 and 75:
HuCAL antibody directed against a c
Page 76 and 77:
hand, the end of exclusivity in Eur
Page 78 and 79:
Generic Prescription Medicines The
Page 80 and 81: Ben Venue - a world leader in steri
Page 82 and 83: Mara Lovera, Buenos Aires, Argentin
Page 84 and 85: Consumer Health Care Our Consumer H
Page 86 and 87: Switching reinforces the trend towa
Page 88 and 89: Alexander (left) and Christopher pl
Page 90 and 91: Animal Health The sound progress of
Page 92 and 93: located, trained and placed with fi
Page 94 and 95: Our Customer Orientation Our custom
Page 96 and 97: On a biopharmaceutical compound’s
Page 98 and 99: Pharmaceuticals Production Our Phar
Page 100 and 101: Counterfeits - a real threat for pa
Page 102 and 103: Group Management Report 2006
Page 104 and 105: companies lost their patent protect
Page 106 and 107: To summarise, we see the success of
Page 108 and 109: Production Production sites belongi
Page 110 and 111: In the area of HIV/AIDS therapy, we
Page 112 and 113: only 2 %. The region’s overall ne
Page 114 and 115: of the cash flow, which rose by EUR
Page 116 and 117: Report on expected developments The
Page 118 and 119: Consolidated Financial Statements 2
Page 120 and 121: C. H. Boehringer Sohn Grundstücksv
Page 122 and 123: C. H. Boehringer Sohn, Ingelheim Co
Page 124 and 125: C. H. Boehringer Sohn, Ingelheim St
Page 126 and 127: The following subsidiaries were exe
Page 128 and 129: 2 Accounting and evaluation methods
Page 132 and 133: 3.3 Financial assets (in millions o
Page 134 and 135: Pension provisions Boehringer Ingel
Page 136 and 137: 4 Notes to the consolidated profit
Page 138 and 139: 4.7 Holding income (in millions of
Page 140 and 141: Other mandatory disclosures accordi
Page 142 and 143: Derivative financial instruments at
Page 144 and 145: With the following exception, our a
Page 146 and 147: Product name Active ingredient Indi
Page 156 and 157: Comparison of Balance Sheets/ Finan
show all

Annual Report 2006 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?